Cyclacel Pharmaceuticals' abstracts on cell cycle inhibitor drugs selected for presentation at AACR meeting

NewsGuard 100/100 Score
Apr 2 2010

Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) today announced that six abstracts highlighting translational and preclinical data for Cyclacel's cell cycle inhibitor drugs have been selected for presentation at the American Association of Cancer Research (AACR) Annual Meeting, being held from April 17-21, 2010, in Washington, DC.

The abstracts can be accessed through the AACR website, www.aacr.org. Abstract titles are provided below. Please note that according to AACR policy, all data are embargoed until the time of the beginning of the presentation.

SOURCE Cyclacel Pharmaceuticals, Inc.

Posted in: Medical Science News | Pharmaceutical News

Tags: , , , , , , , , , , , , , , ,

Comments (0)

Suggested Reading

First-of-its-kind AI tool predicts patient response to cancer drugs at single-cell resolution
Scientists map all yeast proteins across cell cycle for the first time
Research unveils bispecific antibodies for B-cell lymphoma treatment
New technique allows scientists to study the fatty contents of cancer cells
Study reveals molecular changes in brain cells with Lewy bodies
Triple-negative breast cancer patients with high immune cell levels have lower relapse risk after surgery
Proteasomes: Expanding roles beyond cellular waste management
Discovery of new vascular cell type may pave way for novel strategies to treat cardiovascular diseases

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
DELiVR's virtual reality training speeds up cell detection in complex brain datasets